Janux Therapeutics Overview
- Year Founded
-
2017
- Status
-
Public
- Employees
-
114
- Stock Symbol
-
JANX
- Share Price
-
$10.08
- (As of Friday Closing)
Janux Therapeutics General Information
Description
Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. The proprietary technology of the company has enabled the development of distinct bispecific platforms: Tumor Activated T Cell Engagers (TRACTr), Tumor Activated Immunomodulators (TRACIr), and Adaptive Immune Response Modulator (ARM) platforms. The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain.
Contact Information
Website
www.januxrx.comCorporate Office
- 10955 Vista Sorrento Parkway
- Suite 200
- San Diego, CA 92130
- United States
Corporate Office
- 10955 Vista Sorrento Parkway
- Suite 200
- San Diego, CA 92130
- United States
Janux Therapeutics Stock Performance
As of 20-Nov-2026, Janux Therapeutics’s stock price is $10.08. Its current market cap is $617M with 61.2M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $10.08 | $10.29 | $10.05 - $35.34 | $617M | 61.2M | 955K | -$1.59 |
Janux Therapeutics Financials Summary
As of 30-Sep-2026, Janux Therapeutics has a trailing 12-month revenue of $23.3M.
|
In Thousands, USD |
TTM 30-Sep-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 106,520 | (136,293) | 2,504,601 | 170,386 |
| Revenue | 23,289 | 10,000 | 10,588 | 8,083 |
| EBITDA | (137,704) | (155,638) | (96,787) | (71,024) |
| Net Income | (99,849) | (113,625) | (68,994) | (58,293) |
| Total Assets | 983,655 | 1,001,565 | 1,061,516 | 380,407 |
| Total Debt | 20,380 | 22,139 | 23,025 | 24,542 |
Janux Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Janux Therapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|
Janux Therapeutics Comparisons
Industry
Financing
Details
Janux Therapeutics Competitors (41)
One of Janux Therapeutics’s 41 competitors is Carisma Therapeutics, a Formerly VC-backed company based in Philadelphia, PA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Carisma Therapeutics | Formerly VC-backed | Philadelphia, PA | ||||
| Dynavax Technologies | Formerly VC-backed | Emeryville, CA | ||||
| Adaptimmune Therapeutics | Formerly VC-backed | Abingdon, United Kingdom | ||||
| CytomX Therapeutics | Formerly VC-backed | South San Francisco, CA | ||||
| Cellectis | Formerly VC-backed | Paris, France |
Janux Therapeutics Patents
Janux Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026236153-A1 | Compositions and methods related to tumor activated antibodies | Pending | 06-May-2025 | ||
| US-20260226170-A1 | Multispecific polypeptides and methods of use thereof | Pending | 05-Feb-2025 | ||
| WO-2026169835-A1 | Multispecific polypeptides and methods of use thereof | Pending | 05-Feb-2025 | ||
| US-20260234257-A1 | T cell engagers and methods of use thereof | Pending | 05-Feb-2025 | ||
| WO-2026169855-A1 | T cell engagers and methods of use thereof | Pending | 05-Feb-2025 | C12N5/0636 |
Janux Therapeutics Signals
Janux Therapeutics ESG
Risk Overview
Risk Rating
Updated November, 04, 2026
34.84 | High Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 13,593
Rank
Percentile
Pharmaceuticals
Industry
of 852
Rank
Percentile
Biotechnology
Subindustry
of 431
Rank
Percentile
Janux Therapeutics FAQs
-
When was Janux Therapeutics founded?
Janux Therapeutics was founded in 2017.
-
Where is Janux Therapeutics headquartered?
Janux Therapeutics is headquartered in San Diego, CA.
-
What is the size of Janux Therapeutics?
Janux Therapeutics has 114 total employees.
-
What industry is Janux Therapeutics in?
Janux Therapeutics’s primary industry is Drug Discovery.
-
Is Janux Therapeutics a private or public company?
Janux Therapeutics is a Public company.
-
What is Janux Therapeutics’s stock symbol?
The ticker symbol for Janux Therapeutics is JANX.
-
What is the current stock price of Janux Therapeutics?
As of 20-Nov-2026 the stock price of Janux Therapeutics is $10.08.
-
What is the current market cap of Janux Therapeutics?
The current market capitalization of Janux Therapeutics is $617M.
-
What is Janux Therapeutics’s current revenue?
The trailing twelve month revenue for Janux Therapeutics is $23.3M.
-
Who are Janux Therapeutics’s competitors?
Carisma Therapeutics, Dynavax Technologies, Adaptimmune Therapeutics, CytomX Therapeutics, and Cellectis are some of the 41 competitors of Janux Therapeutics.
-
What is Janux Therapeutics’s annual earnings per share (EPS)?
Janux Therapeutics’s EPS for 12 months was -$1.59.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process